Science

Rami Manochakian: MARIPOSA Trial and Latest Developments in the Treatment of EGFR+ NSCLC

Rami Manochakian/X

Jun 30, 2025, 14:51

Rami Manochakian: MARIPOSA Trial and Latest Developments in the Treatment of EGFR+ NSCLC

Rami Manochakian, Vice President of the North American Neuroendocrine Tumor Society, shared a post on X about a paper he co-authored with colleagues published in ASCO Daily News:

“Hot off the press.

Just published on ASCO Daily News.

Editorial Article by our team, Mayo Clinic Comprehensive Cancer Center on:

MARIPOSA trial and latest developments in the Treatment of EGFR+ non-small cell lung cancer (NSCLC).

Very proud of outstanding 1st author/mentee, chief fellow Reema Tawfiq, and excited to co-author first article with my amazing friend/colleague and new chair Vamsi Velcheti.”

Title: The Butterfly Effect: Rethinking First-Line Therapy in Advanced EGFR-Mutant NSCLC After MARIPOSA

Authors: Reema Tawfiq, Rami Manochakian, Vamsi Velcheti

You can read the Full Article in ASCO Daily News.

Rami Manochakian: MARIPOSA Trial and Latest Developments in the Treatment of EGFR+ NSCLC

More posts featuring Rami Manochakian.

ASCO Daily News cancer MARIPOSA trial Mayo Clinic Comprehensive Cancer Center non small cell lung cancer NSCLC OncoDaily Oncology Rami Manochakian Reema Tawfiq Vamsi Velcheti

Garo Armen Shares a Personal Story Driving Agenus' Mission in Cancer Care

Dr. Oliver Bogler, PhD: Leaving the National Cancer Institute

Oncologist Near Me – Rana McKay: A Rising Force in Genitourinary Cancer Research and Care

Sibylle Loibl: Final survival Results from the PENELOPE-B trial published in Annals of Oncology

Yvonne Awards 2025: Honoring Global Oncology Leaders at ASCO’s Most Inspiring Night